Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

04. Dezember 2012 07:00 ET | Quelle: Cleveland BioLabs, Inc.

Cleveland BioLabs to Present at Oppenheimer 23rd Annual Healthcare Conference

BUFFALO, N.Y., Dec. 4, 2012 (GLOBE NEWSWIRE) -- Cleveland BioLabs, Inc. (Nasdaq:CBLI) today announced that the Company is scheduled to present at the Oppenheimer & Co. 23rd Annual Healthcare...
27. November 2012 07:00 ET | Quelle: Cleveland BioLabs, Inc.

Panacela Labs, a Subsidiary of Cleveland BioLabs, Signs Contract for Approximately $4.6 Million With Russian Ministry of Industry and Trade for Development of Xenomycins

BUFFALO, N.Y., Nov. 27, 2012 (GLOBE NEWSWIRE) -- Cleveland BioLabs, Inc. (Nasdaq:CBLI) and Panacela Labs, Inc. today announced award of a contract valued at 146 million rubles, or approximately $4.6...
08. November 2012 07:00 ET | Quelle: Cleveland BioLabs, Inc.

Cleveland BioLabs Reports Third Quarter 2012 Financial Results and Development Progress

BUFFALO, N.Y., Nov. 8, 2012 (GLOBE NEWSWIRE) -- Cleveland BioLabs, Inc. (Nasdaq:CBLI) today reported financial results and development progress for the third quarter and nine months ended September...
06. November 2012 07:00 ET | Quelle: Cleveland BioLabs, Inc.

Cleveland BioLabs Announces Publication of Studies on Effect of Entolimod(TM) (CBLB502) on Graft-Versus-Tumor Activity in Models of Allogeneic Bone Marrow Transplantation

BUFFALO, N.Y., Nov. 6, 2012 (GLOBE NEWSWIRE) -- Cleveland BioLabs, Inc. (Nasdaq:CBLI) announced today the online publication in the Journal of Immunology of a study demonstrating efficacy of...
30. Oktober 2012 07:00 ET | Quelle: Cleveland BioLabs, Inc.

Cleveland BioLabs to Report Third Quarter Financial Results and Provide Operational Update on November 8

BUFFALO, N.Y., Oct. 30, 2012 (GLOBE NEWSWIRE) -- Cleveland BioLabs, Inc. (Nasdaq:CBLI) today announced that on November 8, 2012, before the market opens, it will report its second quarter financial...
25. Oktober 2012 07:02 ET | Quelle: Cleveland BioLabs, Inc.

Department of Defense Chemical Biological and Medical Systems Continues Funding Under Development Contract With Cleveland BioLabs for Entolimod(TM) (CBLB502)

BUFFALO, N.Y., Oct. 25, 2012 (GLOBE NEWSWIRE) -- Cleveland BioLabs, Inc. (Nasdaq:CBLI) today announced that the U.S. Department of Defense (DoD) Chemical Biological and Medical Systems (CBMS)...
19. Oktober 2012 09:01 ET | Quelle: Cleveland BioLabs, Inc.

Cleveland BioLabs Prices $15 Million Public Offering of Common Stock and Warrants

BUFFALO, N.Y., Oct. 19, 2012 (GLOBE NEWSWIRE) -- Cleveland BioLabs, Inc. (Nasdaq:CBLI) announced today that it has priced an underwritten public offering of 7,500,000 units at a price to the public of...
18. Oktober 2012 16:05 ET | Quelle: Cleveland BioLabs, Inc.

Cleveland BioLabs Announces Proposed Public Offering of Common Stock and Warrants

BUFFALO, N.Y., Oct. 18, 2012 (GLOBE NEWSWIRE) -- Cleveland BioLabs, Inc. (Nasdaq:CBLI) today announced today that it intends to offer shares of its common stock and warrants to purchase shares of its...
18. Oktober 2012 07:00 ET | Quelle: Cleveland BioLabs, Inc.

Cleveland BioLabs Submits Proposal to BARDA for Development Funding for Entolimod(TM) (CBLB502)

BUFFALO, N.Y., Oct. 18, 2012 (GLOBE NEWSWIRE) -- Cleveland BioLabs, Inc. (Nasdaq:CBLI) today announced it has submitted a proposal to the Biomedical Advanced Research and Development Authority of the...
10. Oktober 2012 09:04 ET | Quelle: Cleveland BioLabs, Inc.

Cleveland BioLabs and Incuron Announce Start of Phase 1 Trial for CBL0137

BUFFALO, N.Y., Oct. 10, 2012 (GLOBE NEWSWIRE) -- Cleveland BioLabs, Inc. (Nasdaq:CBLI) and Incuron, LLC, a joint venture between the Company and Bioprocess Capital Ventures, today announced that the...

Vorherige Seite